Sign in Subscribe

Mo Elsafy, MD MSc

Mo Elsafy, MD MSc
Tozorakimab’s Broad COPD Bet Hinges on Biomarker Freedom and Durable Safety

COPD, Tozorakimab, Biologics, Respiratory

Tozorakimab’s Broad COPD Bet Hinges on Biomarker Freedom and Durable Safety

Chronic obstructive pulmonary disease remains a high-burden condition even after optimized inhaled therapy, and the current biologic era has left a large refractory population without a targeted systemic option. Tozorakimab enters that gap with a first-in-class dual IL-33 strategy that aims to expand biologic treatment beyond the eosinophilic restrictions that

By Beloo Mirakhur, MD PhD, Dr. Gina Ayala, Mo Elsafy, MD MSc, Jitesh Rana, MD
Zilganersen ASO Reverses Functional Decline in Alexander Disease Ahead of 2026 PDUFA

Zilganersen, Alexander Disease, Rare Disease, Neurology, FDA PDUFA

Zilganersen ASO Reverses Functional Decline in Alexander Disease Ahead of 2026 PDUFA

First-in-class antisense oligonucleotide demonstrates age-dependent functional improvements and robust biomarker reduction, overcoming the absolute limitations of palliative standard of care. See Disclaimer below * Alexander disease is an ultra-rare leukodystrophy that has, until now, sat entirely outside the reach of disease-modifying therapy. Global prevalence sits between 1 in 1,000,000

By Jitesh Rana, MD, Dr. Gina Ayala, Beloo Mirakhur, MD PhD, Mo Elsafy, MD MSc
Ultragenyx's DTX301 Hits Primary Endpoint in Phase 3 OTC Deficiency Trial — But First-Generation AAV Faces Biological and Competitive Limits

Uncategorized

Ultragenyx's DTX301 Hits Primary Endpoint in Phase 3 OTC Deficiency Trial — But First-Generation AAV Faces Biological and Competitive Limits

Enh3ance Study Delivers Statistically Significant Ammonia Reduction and Scavenger Tapering Versus Placebo, Yet Neonatal Exclusion, Seroprevalence Barriers, and Advancing mRNA and Gene Editing Rivals Define the Ceiling for a Curative Therapy. See Disclaimer below * For the estimated 10,000 people living with Ornithine Transcarbamylase (OTC) deficiency in commercially accessible geographies,

By Mo Elsafy, MD MSc, Jitesh Rana, MD
Elegrobart's Zero Hearing Loss and Subcutaneous Convenience Rewrite the Playbook for Thyroid Eye Disease

Thyroid Eye Disease, Elegrobart, Phase 3, VRDN-003

Elegrobart's Zero Hearing Loss and Subcutaneous Convenience Rewrite the Playbook for Thyroid Eye Disease

Phase 3 REVEAL-1 data establishes a differentiated safety profile for Elegrobart, utilizing an extended half-life YTE mutation and Q8W dosing to bypass the severe sensorineural hearing loss characteristic of current intravenous IGF-1R therapies. See Disclaimer below * Thyroid Eye Disease is a disfiguring, potentially blinding autoimmune condition marked by severe ocular

By Beloo Mirakhur, MD PhD, Dr. Gina Ayala, Mo Elsafy, MD MSc, Jitesh Rana, MD
Sutacimig in Glanzmann Thrombasthenia: From Reactive Rescue to Subcutaneous Prophylaxis

Glanzmann Thrombasthenia, Sutacimig, Hematology, Rare Diseases, Prophylaxis

Sutacimig in Glanzmann Thrombasthenia: From Reactive Rescue to Subcutaneous Prophylaxis

Phase 2 data from HMB-001-CL101 positions sutacimig as a viable prophylactic standard of care, with particular relevance for the alloimmunized subpopulation where current options have effectively run out. See Disclaimer below * Glanzmann Thrombasthenia (GT) is an ultra-rare autosomal recessive bleeding disorder caused by a genetic deficiency or dysfunction in the

By Jitesh Rana, MD, Dr. Gina Ayala, Mo Elsafy, MD MSc, Beloo Mirakhur, MD PhD, ClinRM staff
Zasocitinib: JH2 Selectivity, Phase 3 Efficacy, and the Road to Best-in-Class TYK2 Status in Plaque Psoriasis

Zasocitinib, Plaque Psoriasis, TYK2 Inhibitors, TAK-279, Dermatology

Zasocitinib: JH2 Selectivity, Phase 3 Efficacy, and the Road to Best-in-Class TYK2 Status in Plaque Psoriasis

Phase 3 LATITUDE data positions zasocitinib well above apremilast, while the pending NCT06973291 head-to-head trial against deucravacitinib will ultimately determine best-in-class standing among TYK2 inhibitors. See Disclaimer below * Plaque psoriasis affects approximately 7 million patients in the US, roughly 2.0 to 2.4 million of whom carry moderate-to-severe disease.

By Jitesh Rana, MD, Mo Elsafy, MD MSc, Beloo Mirakhur, MD PhD, Dr. Gina Ayala
Dual-Targeting Mechanism Achieves Lesion Suppression but Severe Hepatotoxicity Precludes Frontline Utility

Neurology

Dual-Targeting Mechanism Achieves Lesion Suppression but Severe Hepatotoxicity Precludes Frontline Utility

Phase 3 data demonstrates fenebrutinib effectively halts acute peripheral inflammation, but the therapeutic window is aggressively narrowed by drug-induced liver injury risks and necessary hepatic monitoring protocols. See Disclaimer below * The global Relapsing Multiple Sclerosis (RMS) market operates as a massive commercial theater, encompassing approximately 800,000 prevalent patients in

By Jitesh Rana, MD, Mo Elsafy, MD MSc